Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Early Breast Cancer
Interventions: DRUG: TALAZOPARIB
Sponsor: Pfizer